AUTHORS
Michael Haddadin, MBBS, MS, Moataz Ellithi, MD2, Krishna Gundabolu, MBBS3, Snegha Ananth, MD4, Lori Maness, MD5, Christopher D'Angelo, MD, MS6, Tanya Wildes, MD,MSc7, Nicole A Spurgeon, RD8, Jana K Ponce, RD, PhD9, Lynette Smith10, Fang Qiu11, Vijaya Raj Bhatt, MBBS, MS12
AFFILIATIONS
1 Unmc College of Medicine, Omaha, Nebraska, United States
2 Unmc College of Medicine, Omaha, Nebraska, United States
3 Unmc College of Medicine, Omaha, Nebraska, United States
4 Unmc College of Medicine, Omaha, Nebraska, United States
5 Unmc College of Medicine, Omaha, Nebraska, United States
6 Unmc College of Medicine, Omaha, Nebraska, United States
7 Unmc College of Medicine, Omaha, Nebraska, United States
8 Nebraska Medical Center, Omaha, Nebraska, United States
9 University of Nebraska Medical Center, Omaha, Nebraska, United States
10 University of Nebraska Medical Center, Omaha, Nebraska, United States
11 University of Nebraska Medical Center, Omaha, Nebraska, United States
12 Unmc College of Medicine, Omaha, Nebraska, United States
ABSTRACT
Background: Conditioning regimens in allogeneic hematopoietic stem cell transplant (allo-HSCT) are associated with decreased oral intake, mucositis, weight loss, and malnutrition in up to 50% of transplant recipients. These complications synergistically may disrupt gut epithelial barrier and reduce diversity of gut microbiome, thus promoting bacterial translocation, inflammatory cascade, and acute graft-versus-host disease (GVHD) of the gut. Malnutrition and acute GVHD act synergistically to increase non-relapse (NRM) and transplant-related mortality. In addition to optimizing pharmacological GVHD prophylaxis, an opportunity exists to leverage nutritional strategies to mitigate disruption of gut microbiome and epithelial barrier. While parenteral nutrition (PN) is used as artificial supplemental nutrition, it carries risks of hyperglycemia, infections, and other complications which may further impair integrity of the intestinal barrier. In contrast, early enteral nutrition (EN) is a widely available, low-risk, low-cost intervention that may reduce the risk of gut GVHD by promoting mucosal membrane recovery and preservation of gut microbiome. Prior retrospective studies and small non-randomized clinical trials suggest that EN in transplant recipients is associated with lower risk of GVHD, reduced NRM, and shorter time for engraftment. Despite guideline recommendations from different clinical nutritional societies, a lack of appropriately powered randomized controlled trial limits its widespread adoption. This rigorous trial builds on our institutional experience over the past 2 years to bridge this critical knowledge gap. It will provide the first adequately powered randomized data to evaluate whether EN reduces the risk of GVHD and improving the safety of allogenic stem cell transplant (ClinicalTrials.gov ID NCT07315165).
Study Design and Methods: This is a single-center, phase II, randomized controlled trial comparing EN versus standard of care in adults undergoing allo-HSCT. Key inclusion criteria include: adults 19 years or older, with a diagnosis of hematological malignancy or blood disorder such as aplastic anemia, undergoing allo-HSCT (regardless of donor type or conditioning intensity). Key exclusion criteria include: uncorrected anatomical deformities preventing proper placement of nasogastric tube, nasopharyngeal infections, and chronic gastrointestinal conditions causing malabsorption or diarrhea. Participants will be randomized 1:1 to either EN or control arm. Participants assigned to EN will have a nasogastric feeding tube placed 1-day post-transplant and receive a commercially available tube feed formula. Enteral nutrition will continue for at least 7 days, or improvement in appetite and mucositis, which coincides with the time of engraftment. Participants assigned control arm will initiate conventional oral nutrition as tolerated with a balanced general diet. Supplemental enteral or parenteral nutrition may be initiated in the control group when clinically indicated, at the discretion of the care team. We hypothesize that early EN will decrease the incidence of severe lower gut GVHD. The target accrual is 112 patients (56 participants per arm) allowing 90% power to detect a hazard ratio of 0.447 at a two-sided significance level of 0.049.
The primary objective is to compare the cumulative incidence of severe lower gut acute GVHD, defined as stages 3-4 as defined by the Mount Sinai Acute GVHD International Consortium criteria by day 100 post-transplant. The secondary objectives include to compare the cumulative incidence of stage 2-4 lower gut acute GVHD, grade 2-4 overall GVHD, changes in weight, physical function and health-related quality of life from baseline to 100 days post-transplant, and time to neutrophil and platelet engraftment. The primary analysis will follow the intention-to-treat principle. Time to stage 3-4 lower gut acute GVHD through 100 days will be analyzed as a competing-risks endpoint. Changes in weight, physical function and health-related quality of life will be described and compared within and between groups using paired and two-sample t-tests and other appropriate nonparametric tests, with linear models to evaluate trajectories over time. Lastly, serum and stool samples will be collected at baseline and follow-up to compare changes in gut integrity and microbiome as translational endpoints. The study is currently open and accruing patients.
DISCLOSURES
Michael Haddadin, MBBS, MS: Syndax - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony)